Literature DB >> 22023456

Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study.

M C S Wong1, R K C Lau, J Y Jiang, S M Griffiths.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Angiotensin-converting enzyme inhibitors (ACEI) are among the most commonly used antihypertensive agents worldwide. Factors associated with their discontinuation in clinical practice are not well defined as studies undertaken in different ethnic populations have yielded conflicting result. We aimed to identify predictors of ACEI discontinuation among Chinese patients.
METHODS: We used a validated clinical database for this cohort study. We included all adult patients aged ≥ 18 years who visited any primary care clinic in one Territory of Hong Kong and who were prescribed an ACEI from January 2004 to June 2007. The cumulative incidence of discontinuation 180 days after prescription of an ACEI was measured. Factors associated with discontinuation were evaluated by multiple regression analyses.
RESULTS: Among 9398 eligible patients, 14·0% discontinued their prescriptions. After controlling for patient's age, gender, socio-economic status, service type, district of residence, visit type and number of comorbidities, patients aged 70 or above [adjusted odds ratio (AOR) = 1·27, 95% CI 1·04-1·56, P = 0·022], male subjects (AOR = 1·21, 95% CI 1·05-1·40, P = 0·008), new visitors (AOR = 0·64, 95% CI 0·55-0·75, P < 0·001), patients who obtained their prescriptions in Family Medicine Specialist Clinic (FMSC) (AOR = 1·43, 95% CI 1·14-1·79, P = 0·002), patients who lived in the less urbanized district (AOR = 1·96, 95% CI 1·55-2·48, P < 0·001) and the most rural district (AOR = 1·24, 95% CI 1·03-1·49, P = 0·027), and patients with no comorbidity, were more likely to discontinue their medications. WHAT IS NEW AND
CONCLUSION: Physicians should pay attention to adherence problems particularly when prescribing ACEI to male patients, those who are older than 70 years, have no comorbidity, live in less urbanized or more rural areas, qualify for fee-waiver, are new attendees of consultations or obtain their ACEI prescriptions in FMSC. Future research should evaluate the reasons for ACEI discontinuation among these higher-risk groups.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023456     DOI: 10.1111/j.1365-2710.2011.01300.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study.

Authors:  Seyed Hamidreza Mahmoudpour; Folkert W Asselbergs; Patrick C Souverein; Anthonius de Boer; Anke H Maitland-van der Zee
Journal:  Br J Clin Pharmacol       Date:  2018-07-24       Impact factor: 4.335

2.  End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.

Authors:  Michal Shani; Shlomo Vinker; Leonid Feldman
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-02-08       Impact factor: 3.738

3.  Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.

Authors:  Seyed Hamidreza Mahmoudpour; Folkert W Asselbergs; Catherine E de Keyser; Patrick C Souverein; Albert Hofman; Bruno H Stricker; Anthonius de Boer; Anke-Hilse Maitland-van der Zee
Journal:  Int J Clin Pharm       Date:  2015-07-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.